{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040810","form_type":"8-K","ticker":"SHPH","cik":"0001757499","company_name":"Shuttle Pharmaceuticals Holdings, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.329539+00:00","generated_at":"2026-06-08T03:52:32.994975+00:00","sec_items":["2.02","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Shuttle Pharma gets positive FDA feedback for Ropidoxuridine Phase 2; cash $6.8M","bullets":["Positive FDA feedback in Type B PIND meeting for Ropidoxuridine; IND submission imminent to start Phase 2 trial for glioblastoma.","Exclusive license from Georgetown University for predictive biomarker test for prostate cancer radiation therapy.","Q3 2023 operating expenses (excl non-cash) $1.6M; cash, cash equivalents and marketable securities $6.8M at Sep 30, 2023.","Expanded patent coverage on HDAC inhibitor platform; published manuscript on SP-2-225 immune response post-radiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040810","json":"https://secwatch.observer/filing/0001493152-23-040810.json","markdown":"https://secwatch.observer/filing/0001493152-23-040810.md","text":"https://secwatch.observer/filing/0001493152-23-040810.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757499/000149315223040810/0001493152-23-040810-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757499/000149315223040810/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:52:32.994975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0241e9e7be6db241c34030e70881ad9abec54eb8","claim":"Shuttle Pharmaceuticals Holdings, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"issued a press release providing a corporate update in connection with the filing of our quarterly report on Form 10-Q for the period ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315223040810/0001493152-23-040810-index.htm","confidence":0.6,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}